Zein nanoparticles containing ceftazidime and tobramycin: antibacterial activity against Gram-negative bacteria

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Bassetti M, Peghin M, Vena A, Giacobbe DR. Treatment of infections due to MDR Gram-negative bacteria. Front. Med. 6(74), 1–12 (2019).
  Google Scholar
• 2. Kofteridis DP, Andrianaki AM, Maraki S et al. Treatment pattern, prognostic factors, and outcome in patients with infection due to pan-drug-resistant Gram-negative bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 39(5), 965–970 (2020).
  Medline CASGoogle Scholar
• 3. Coppola N, Maraolo AE, Onorato L et al. Epidemiology, mechanisms of resistance and treatment algorithm for infections due to carbapenem-resistant Gram-negative bacteria: an expert panel opinion. Antibiotics 11(9), 1263 (2022).
  CASGoogle Scholar
• 4. Chung PY. The emerging problems of Klebsiella pneumoniae infections: carbapenem resistance and biofilm formation. FEMS Microbiol. Lett. 363(20), 219 (2016).
  Google Scholar
• 5. Ruhal R, Kataria R. Biofilm patterns in Gram-positive and Gram-negative bacteria. Microbiol. Res. 251, 126829 (2021).
  Medline CASGoogle Scholar
• 6. Syaiful I, Widodo ADW, Endraswari PD, Alimsardjono L, Utomo B, Arfijanto MV. The association between biofilm formation ability and antibiotic resistance phenotype in clinical isolates of Gram-negative bacteria: a cross-sectional study. Bali Med. J. 12(1), 1014–1020 (2023).
  Google Scholar
• 7. Jones TE, Selby PR, Mellor CS, Cheam DB. Ceftazidime stability and pyridine toxicity during continuous iv infusion. Am. J. Health Syst. Pharm. 76(4), 200–205 (2019). • The need to use nanotechnology to improve therapeutic approaches using antimicrobials.
  MedlineGoogle Scholar
• 8. Da Silva Medeiros T, Pinto EC, Cabral LM, de Sousa VP. Tobramycin: a review of detectors used in analytical approaches for drug substance, its impurities and in pharmaceutical formulation. Microchem. J. 160, 105658 (2021).
  Google Scholar
• 9. Zasowski EJ, Rybak JM, Rybak MJ. The β-lactams strike back: ceftazidime-avibactam. Pharm. J. Human Pharm. Drug Ther. 35(8), 755–770 (2015).
  Medline CASGoogle Scholar
• 10. Schwarz C, Taccetti G, Burgel PR, Mulrennan S. Tobramycin safety and efficacy review article. Respir. Med. 195, 106778 (2022).
  MedlineGoogle Scholar
• 11. Michelon H, Tardivel M, Dinh A et al. Efficacy and safety of subcutaneous administration of ceftazidime as a salvage therapy in geriatrics: a case report. Fundam. Clin. Pharmacol. 34(4), 521–524 (2020).
  Medline CASGoogle Scholar
• 12. Irache JM, González-Navarro CJ. Zein nanoparticles as vehicles for oral delivery purposes. Nanomedicine 12(11), 1209–1211 (2017).
  CASGoogle Scholar
• 13. Pascoli M, de Lima R, Fraceto LF. Zein nanoparticles and strategies to improve colloidal stability: a mini-review. Front. Chem. 6, 1–6 (2018).
  MedlineGoogle Scholar
• 14. Campos LAA, Neto AFS, Noronha MCS, de Lima MF, Cavalcanti IMF, Santos-Magalhães NS. Zein nanoparticles for drug delivery: preparation methods and biological applications. Int. J. Pharm. 635, 122754 (2023).
  MedlineGoogle Scholar
• 15. Campos L, de Souza Tavares W, Pena GR, Martin-Pastor M, de Sousa FFO. Design and characterization of ellagic acid-loaded zein nanoparticles and their effect on the antioxidant and antibacterial activities. J. Mol. Liq. 341, 116915 (2021).
  Google Scholar
• 16. de Araujo JTC, Martin-Pastor M, Pérez L, Pinazo A, de Sousa FFO. Development of anacardic acid-loaded zein nanoparticles: physical chemical characterization, stability, and antimicrobial improvement. J. Mol. Liq. 332, 115808 (2021).
  Google Scholar
• 17. Moreno LCGEI, Puerta E, Suárez-Santiago JE, Santos-Magalhães NS, Ramirez MJ, Irache JM. Effect of the oral administration of nanoencapsulated quercetin on a mouse model of Alzheimer's disease. Int. J. Pharm. 517(1–2), 50–57 (2017).
  Medline CASGoogle Scholar
• 18. Cavalcanti IDL, Ximenes RM, Loiola Pessoa OD, Santos Magalhães NS, Lira-Nogueira MC de B. Fucoidan-coated PIBCA nanoparticles containing oncocalyxone A: activity against metastatic breast cancer cells. J. Drug Deliv. Sci. Technol. 65, 102698 (2021).
  CASGoogle Scholar
• 19. Moreno-Sastre M, Pastor M, Esquisabel A et al. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis. Int. J. Pharm. 498(1–2), 263–273 (2016). •• Tobramycin is a main antibiotic in the treatment of bacteria that cause nosocomial infections and methodologies for improving this drug are important targets for combating antimicrobial resistance.
  Medline CASGoogle Scholar
• 20. Da Rosa CG, De Oliveira Brisola Maciel MV, De Carvalho SM et al. Characterization and evaluation of physicochemical and antimicrobial properties of zein nanoparticles loaded with phenolics monoterpenes. Colloids Surf. A Physicochem. Eng. Asp. 481, 337–344 (2015).
  Google Scholar
• 21. Hu C, Wang L-L, Lin Y-Q et al. Nanoparticles for the treatment of oral biofilms: current state, mechanisms, influencing factors, and prospects. Adv. Healthc. Mater. 8(24), e1901301 (2019).
  Medline CASGoogle Scholar
• 22. Liang J, Yan H, Wang X et al. Encapsulation of epigallocatechin gallate in zein/chitosan nanoparticles for controlled applications in food systems. Food Chem. 231, 19–24 (2017).
  Medline CASGoogle Scholar
• 23. Park CE, Park DJ, Kim BK. Effects of a chitosan coating on properties of retinol-encapsulated zein nanoparticles. Food Sci. Biotechnol. 24(5), 1725–1733 (2015).
  CASGoogle Scholar
• 24. Performance standards for antimicrobial susceptibility testing. CLSI (33rd Edition). Lewis JS II (Ed.). Clinical and Laboratory Standards Institute, PA, USA (2023).
  Google Scholar
• 25. Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M. A modified microtiter-plate test for quantification of Staphylococcal biofilm formation. J. Microbiol. Methods 40(2), 175–179 (2000).
  Medline CASGoogle Scholar
• 26. Albano M, Crulhas BP, Alves FCB et al. Antibacterial and anti-biofilm activities of cinnamaldehyde against S. epidermidis. Microb. Pathog. 126, 231–238 (2019).
  Medline CASGoogle Scholar
• 27. Bassetti M, Garau J. Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections. J. Antimicrob. Chemother. 76(Suppl. 4), 23–37 (2021).
  Google Scholar
• 28. Breijyeh Z, Jubeh B, Karaman R. Resistance of Gram-negative bacteria to current antibacterial agents and approaches to resolve it. Molecules 25(6), 1340 (2020).
  Medline CASGoogle Scholar
• 29. Tacconelli E, Carrara E, Savoldi A et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 18(3), 318–327 (2018).
  MedlineGoogle Scholar
• 30. Scudeller L, Righi E, Chiamenti M et al. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli. Int. J. Antimicrob. Agents 57(5), 106344 (2021).
  Medline CASGoogle Scholar
• 31. Giteru SG, Ali MA, Oey I. Recent progress in understanding fundamental interactions and applications of zein. Food Hydrocoll. 120, 106948 (2021).
  CASGoogle Scholar
• 32. Tortorella S, Maturi M, Buratti VV et al. Zein as a versatile biopolymer: different shapes for different biomedical applications. RSC Adv. 11(62), 39004–39026 (2021).
  Medline CASGoogle Scholar
• 33. Danaei M, Dehghankhold M, Ataei S et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 10(2), 57 (2018).
  MedlineGoogle Scholar
• 34. Mistry A, Glud SZ, Kjems J et al. Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium. J. Drug Target 17(7), 543–552 (2009).
  Medline CASGoogle Scholar
• 35. Larese Filon F, Mauro M, Adami G, Bovenzi M, Crosera M. Nanoparticles skin absorption: new aspects for a safety profile evaluation. Regul. Toxicol. Pharmacol. 72(2), 310–322 (2015).
  MedlineGoogle Scholar
• 36. Fröhlich E, Roblegg E. Oral uptake of nanoparticles: human relevance and the role of in vitro systems. Arch. Toxicol. 90(10), 2297–2314 (2016). • Benefits of using nanotechnology in the use of new antimicrobial approaches.
  MedlineGoogle Scholar
• 37. Zhang Y, Niu Y, Luo Y et al. Fabrication, characterization and antimicrobial activities of thymol-loaded zein nanoparticles stabilized by sodium caseinate–chitosan hydrochloride double layers. Food Chem. 142, 269–275 (2014).
  Medline CASGoogle Scholar
• 38. Yan X, Li M, Xu X, Liu X, Liu F. Zein-based nano-delivery systems for encapsulation and protection of hydrophobic bioactives: a review. Front. Nutr. 9, 999373 (2022).
  MedlineGoogle Scholar
• 39. Wijesooriya C, Budai M, Budai L, Szilasi ME, Petrikovics I. Optimization of liposomal encapsulation for ceftazidime for developing a potential eye drop formulation. J. Basic Clin. Pharm. 4(3), 73–75 (2013).
  Medline CASGoogle Scholar
• 40. Farzampanah L, Chitsaz M, Tabandeh H, Hajihosseini R, Mansouri S. Preparation and investigation of in vitro effect of liposomal ceftazidime on the resistant Pseudomonas aeruginosa. Adv. Biol. Res. 9(3), 105–111 (2017). •• Liposomal formulations of ceftazidime have great potential for the treatment of infections caused by P. aeruginosa, requiring application in in vivo studies.
  Google Scholar
• 41. Silva MM, Calado R, Marto J, Bettencourt A, Almeida AJ, Gonçalves LMD. Chitosan nanoparticles as a mucoadhesive drug delivery system for ocular administration. Mar. Drugs 15(12), 354–370 (2017).
  MedlineGoogle Scholar
• 42. Al-Nemrawi NK, Alshraiedeh NH, Zayed AL, Altaani BM. Low molecular weight chitosan-coated PLGA nanoparticles for pulmonary delivery of tobramycin for cystic fibrosis. Pharmaceuticals 11(1), 14–28 (2018).
  MedlineGoogle Scholar
• 43. Hedayati Ch M, Abolhassani Targhi A, Shamsi F et al. Niosome-encapsulated tobramycin reduced antibiotic resistance and enhanced antibacterial activity against multidrug-resistant clinical strains of Pseudomonas aeruginosa. J. Biomed. Mater. Res. A 109(6), 966–980 (2021).
  MedlineGoogle Scholar
• 44. Zhang H, van Os WL, Tian X et al. Development of curcumin-loaded zein nanoparticles for transport across the blood–brain barrier and inhibition of glioblastoma cell growth. Biomater. Sci. 9(21), 7092–7103 (2021).
  Medline CASGoogle Scholar
• 45. Reboredo C, González-Navarro CJ, Martínez-Oharriz C, Martínez-López AL, Irache JM. Preparation and evaluation of PEG-coated zein nanoparticles for oral drug delivery purposes. Int. J. Pharm. 597, 120287 (2021).
  Medline CASGoogle Scholar
• 46. Leena MM, Anukiruthika T, Moses JA, Anandharamakrishnan C. Co-delivery of curcumin and resveratrol through electrosprayed core-shell nanoparticles in 3D printed hydrogel. Food Hydrocoll. 124, 107200 (2022).
  CASGoogle Scholar
• 47. Rozenberg M, Shoham G. FTIR spectra of solid poly-l-lysine in the stretching NH mode range. Biophys. Chem. 125(1), 166–171 (2007).
  Medline CASGoogle Scholar
• 48. Thakare Y, Dharaskar S, Palkar R. FTIR spectroscopy and microscopy in biomedical nanotechnology. In: Analytical Techniques for Biomedical Nanotechnology. Kaushik ASrinivasan SSMishra YK (Ed.). IOP Publishing, Bristol, UK, 4–19 (2023).
  Google Scholar
• 49. Bianchera A, Bettini R. Polysaccharide nanoparticles for oral controlled drug delivery: the role of drug–polymer and interpolymer interactions. Expert Opin. Drug Deliv. 17(10), 1345–1359 (2020).
  Medline CASGoogle Scholar
• 50. Osório LR, Meneguin AB, da Silva HB, Barreto HM, Osajima JA, da Silva Filho EC. Evaluation of physico-chemical properties and antimicrobial synergic effect of ceftazidime-modified chitosan. J. Therm. Anal. Calorim. 134(3), 1629–1636 (2018). •• The use of combined therapy presents an important benefit for combating antimicrobial resistance.
  CASGoogle Scholar
• 51. Ge X, Sun Y, Kong J et al. The thermal resistance and targeting release of zein-sodium alginate binary complexes as a vehicle for the oral delivery of riboflavin. J. Food Sci. Technol. 60(1), 92–102 (2023).
  Medline CASGoogle Scholar
• 52. Rosasco MA, Bonafede SL, Faudone SN, Segall AI. Compatibility study of tobramycin and pharmaceutical excipients using differential scanning calorimetry, FTIR, DRX, and HPLC. J. Therm. Anal. Calorim. 134(3), 1929–1941 (2018).
  CASGoogle Scholar
• 53. Pereira LA, da Silva Reis L, Batista FA, Mendes JÁ, Osajima JÁ, Silva-Filho EC. Biological properties of chitosan derivatives associated with the ceftazidime drug. Carbohydr. Polym. 222, 115002 (2019).
  Medline CASGoogle Scholar
• 54. Turasan H, Kokini JL. Advances in understanding the molecular structures and functionalities of biodegradable zein-based materials using spectroscopic techniques: a review. Biomacromolecules 18(2), 331–354 (2017).
  Medline CASGoogle Scholar
• 55. Girija Aswathy R, Sivakumar B, Brahatheeswaran D et al. Biocompatible fluorescent zein nanoparticles for simultaneous bioimaging and drug delivery application. Adv. Nat. Sci. Nanosci. Nanotechnol. 3(2), 025006 (2012).
  Google Scholar
• 56. Jacinto TA, Oliveira B, Miguel SP, Ribeiro MP, Coutinho P. Ciprofloxacin-loaded zein/hyaluronic acid nanoparticles for ocular mucosa delivery. Pharmaceutics 14(8), 1557 (2022).
  Medline CASGoogle Scholar
• 57. Selvakannan PR, Mandal S, Phadtare S, Pasricha R, Sastry M. Capping of gold nanoparticles by the amino acid lysine renders them water-dispersible. Langmuir 19(8), 3545–3549 (2003).
  CASGoogle Scholar
• 58. Masoud MS, Ali AE, Elasala GS, Kolkaila SA. Synthesis, spectroscopic, biological activity and thermal characterization of ceftazidime with transition metals. Spectrochim. Acta A Mol. Biomol. 193, 458–466 (2018).
  Medline CASGoogle Scholar
• 59. da Rosa CG, Sganzerla WG, de Oliveira Brisola Maciel MV et al. Development of poly (ethylene oxide) bioactive nanocomposite films functionalized with zein nanoparticles. Colloids Surf. A Physicochem. Eng. Asp. 586, 124268 (2020).
  Google Scholar
• 60. Piel G, Pirotte B, Delneuville I et al. Study of the influence of both cyclodextrins and L-lysine on the aqueous solubility of nimesulide; isolation and characterization of nimesulide-L-lysine-cyclodextrin complexes. J. Pharm. Sci. 86(4), 475–480 (1997).
  Medline CASGoogle Scholar
• 61. Chang S-C, Lee M-J, Lin H. Preparation of nano- and micrometric ceftazidime particles with supercritical anti-solvent technique. J. Phys. Chem. C 112(38), 14835–14842 (2008).
  CASGoogle Scholar
• 62. Lopes CM, Lobo JMS, Costa P. Formas farmacêuticas de liberação modificada: polímeros hidrifílicos. Rev. Bras. Cienc. Farm. 41, 143–154 (2005).
  CASGoogle Scholar
• 63. Shinde P, Agraval H, Srivastav AK, Yadav UCS, Kumar U. Physico-chemical characterization of carvacrol loaded zein nanoparticles for enhanced anticancer activity and investigation of molecular interactions between them by molecular docking. Int. J. Pharm. 588, 119795 (2020).
  Medline CASGoogle Scholar
• 64. Cui B, Li J, Lai Z et al. Emamectin benzoate-loaded zein nanoparticles produced by antisolvent precipitation method. Polym. Test. 94, 107020 (2021).
  CASGoogle Scholar
• 65. Zhang F, Khan MA, Cheng H, Liang L. Co-encapsulation of α-tocopherol and resveratrol within zein nanoparticles: impact on antioxidant activity and stability. J. Food Eng. 247, 9–18 (2019).
  CASGoogle Scholar
• 66. De Melo APZ, Da Rosa CG, Sganzerla WG et al. Synthesis and characterization of zein nanoparticles loaded with essential oil of Ocimum gratissimum and Pimenta racemosa. Mater. Res. Express. 6(9), 095084 (2019).
  Google Scholar
• 67. Gonçalves da Rosa C, Zapelini de Melo AP, Sganzerla WG et al. Application in situ of zein nanocapsules loaded with Origanum vulgare Linneus and Thymus vulgaris as a preservative in bread. Food Hydrocoll. 99, 105339 (2020).
  Google Scholar
• 68. Yuan Y, Li H, Liu C et al. Fabrication of stable zein nanoparticles by chondroitin sulfate deposition based on antisolvent precipitation method. Int. J. Biol. Macromol. 139, 30–39 (2019).
  Medline CASGoogle Scholar
• 69. Li H, Yuan Y, Zhu J, Wang T, Wang D, Xu Y. Zein/soluble soybean polysaccharide composite nanoparticles for encapsulation and oral delivery of lutein. Food Hydrocoll. 103, 105715 (2020).
  CASGoogle Scholar
• 70. Nunes R, Baião A, Monteiro D, das Neves J, Sarmento B. Zein nanoparticles as low-cost, safe, and effective carriers to improve the oral bioavailability of resveratrol. Drug Deliv. Transl. Res. 10(3), 826–837 (2020).
  Medline CASGoogle Scholar
• 71. Sans-Serramitjana E, Jorba M, Fusté E, Pedraz JL, Vinuesa T, Viñas M. Free and nanoencapsulated tobramycin: effects on planktonic and biofilm forms of Pseudomonas. Microorganisms 5(3), 35 (2017).
  MedlineGoogle Scholar
• 72. Hill M, Cunningham RN, Hathout RM, Johnston C, Hardy JG, Migaud ME. Formulation of antimicrobial tobramycin loaded PLGA nanoparticles via complexation with AOT. J. Funct. Biomater. 10(2), 26 (2019).
  Medline CASGoogle Scholar
• 73. Gómez-Núñez MF, Castillo-López M, Sevilla-Castillo F et al. Nanoparticle-based devices in the control of antibiotic resistant bacteria. Front. Microbiol. 11, 563821 (2020).
  MedlineGoogle Scholar
• 74. Lin YK, Yang SC, Hsu CY, Sung JT, Fang JY. The antibiofilm nanosystems for improved infection inhibition of microbes in skin. Molecules 26(21), 6392 (2021).
  Medline CASGoogle Scholar
• 75. Ratjen F, Brockhaus F, Angyalosi G. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. J. Cyst. Fibros. 8(6), 361–369 (2009).
  Medline CASGoogle Scholar
• 76. de Souza Tavares W, Pena GR, Martin-Pastor M, de Sousa FFO. Design and characterization of ellagic acid-loaded zein nanoparticles and their effect on the antioxidant and antibacterial activities. J. Mol. Liq. 341, 116915 (2021).
  Google Scholar
• 77. Gong S, Wang D, Tao S et al. Facile encapsulation of thymol within deamidated zein nanoparticles for enhanced stability and antibacterial properties. Colloids Surf. A Physicochem. Eng. Asp. 626, 126940 (2021).
  CASGoogle Scholar
• 78. Dos Santos Ramos MA, Da Silva PB, Spósito L et al. Nanotechnology-based drug delivery systems for control of microbial biofilms: a review. Int. J. Nanomedicine 13, 1179–1213 (2018).
  MedlineGoogle Scholar
• 79. Feng W, Zhang L, Yuan Q et al. Effect of sub-minimal inhibitory concentration ceftazidime on the pathogenicity of uropathogenic Escherichia coli. Microb. Pathog. 151, 104748 (2021).
  Medline CASGoogle Scholar
• 80. Alzahrani NM, Booq RY, Aldossary AM et al. Liposome-encapsulated tobramycin and IDR-1018 peptide mediated biofilm disruption and enhanced antimicrobial activity against Pseudomonas aeruginosa. Pharmaceutics 14(5), 960 (2022).
  Medline CASGoogle Scholar
• 81. Kamali E, Jamali A, Izanloo A, Ardebili A. In vitro activities of cellulase and ceftazidime, alone and in combination against Pseudomonas aeruginosa biofilms. BMC Microbiol. 21, 1–10 (2021).
  MedlineGoogle Scholar
• 82. Choi V, Rohn JL, Stoodley P, Carugo D, Stride E. Drug delivery strategies for antibiofilm therapy. Nat. Rev. Microbiol. 21(1), 1–18 (2023).
  Google Scholar
• 83. Vuotto C, Longo F, Pascolini C et al. Biofilm formation and antibiotic resistance in Klebsiella pneumoniae urinary strains. J. Appl. Microbiol. 123(4), 1003–1018 (2017).
  Medline CASGoogle Scholar
• 84. Shebl RI, Elkhatib WF, Badawy MSE. Modulating the transcriptomic profile of multidrug-resistant Klebsiella pneumoniae biofilm formation by antibiotics in combination with zinc sulfate. Ann. Clin. Microbiol. Antimicrob. 22(1), 1–12 (2023).
  MedlineGoogle Scholar
• 85. Li Y, Wang B, Lu F et al. Synergistic inhibitory effect of polymyxin B in combination with ceftazidime against robust biofilm formed by Acinetobacter baumannii with genetic deficiency in AbaI/AbaR quorum sensing. Microbiol. Spectr. 10(1), e01768–21 (2022).
  Medline CASGoogle Scholar
• 86. Guerrieri CG, Gonçalves MT, da Silva AF, Dos Santos ALS, Dos Santos KV, Spano LC. Remarkable antibiofilm activity of ciprofloxacin, cefoxitin, and tobramycin, by themselves or in combination, against enteroaggregative Escherichia coli in vitro. Diagn. Microbiol. Infect. Dis. 107(3), 116048 (2023).
  MedlineGoogle Scholar
• 87. Sun F, Yuan Q, Wang Y et al. Sub-minimum inhibitory concentration ceftazidime inhibits Escherichia coli biofilm formation by influencing the levels of the ibpA gene and extracellular indole. J. Chemother. 32(1), 7–14 (2020).
  Medline CASGoogle Scholar
• 88. Eladawy M, El-Mowafy M, El-Sokkary MMA, Barwa R. Effects of lysozyme, proteinase K, and cephalosporins on biofilm formation by clinical isolates of Pseudomonas aeruginosa. Interdiscip. Perspect. Infect. Dis. 2020, 1–13 (2020).
  Google Scholar
• 89. Fulaz S, Vitale S, Quinn L, Casey E. Nanoparticle-biofilm interactions: the role of the EPS matrix. Trends Microbiol. 27(11), 915–926 (2019).
  Medline CASGoogle Scholar
• 90. Verderosa AD, Totsika M, Fairfull-Smith KE. Bacterial biofilm eradication agents: a current review. Front Chem. 7(824), 1–17 (2019).
  MedlineGoogle Scholar
• 91. Lima RA, de Souza SLX, Lima LA et al. Antimicrobial effect of anacardic acid–loaded zein nanoparticles loaded on Streptococcus mutans biofilms. Braz. J. Microbiol. 51(4), 1623–1630 (2020).
  Medline CASGoogle Scholar
• 92. Liu Y, Shi L, Su L et al. Nanotechnology-based antimicrobials and delivery systems for biofilm-infection control. Chem. Soc. Rev. 48(2), 428–446 (2019). •• Use of nanotechnology as a framework to enhance the antimicrobial activity of antimicrobial molecules by enhancing antibiofilm activity.
  Medline CASGoogle Scholar
• 93. Malaekeh-Nikouei B, Fazly Bazzaz BS, Mirhadi E, Tajani AS, Khameneh B. The role of nanotechnology in combating biofilm-based antibiotic resistance. J. Drug Deliv. Sci. Technol. 60, 101880 (2020).
  CASGoogle Scholar
• 94. Hughes G, Webber MA. Novel approaches to the treatment of bacterial biofilm infections. Br. J. Pharmacol. 174(14), 2237–2246 (2017).
  Medline CASGoogle Scholar